ArticleNature communications2023

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.

Jacopo Chiaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.